In early 2019, I established the Nikean Foundation. The goal of the foundation is to promote research of novel mechanisms for treating mental disorders. A current focus is on psychedelic and associated medicines, including psilocybin, MDMA, and 5 MEO-DMT.

Psychedelic assisted therapy and micro-dosing are just some of the trials being looked at today, and research funding can be elusive as these molecules are in the public domain and the lack of opportunities to profit from drug development have led the major pharmaceuticals to stay away from these promising treatments.

The interim goal of the foundation is to advance psychedelic science by supporting open science partners that promote research, education, and prove the safety and effectiveness of psychedelic medicines versus prescribed clinical medicines when suffering from PTSD, anxiety, depression, and eating disorders.

The end goal is to promote the efficacy of psychedelics globally and to provide clinical facilities, training, and accessibility to the general public.


Our Partners

The Nikean Foundation has partnered to fund research and is developing projects with the University of Toronto (microdosing), Imperial College in the UK (several studies), MAPS (MDMA for anorexia), and Usona Institute (5-Meo DMT Program).

We Value Your Privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking “Accept All”, you consent to our use of cookies.